Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
878 Leser
Artikel bewerten:
(2)

The Power Play by The Market Herald Releases Interviews With Xali Gold, Falcon Gold, Psyched Wellness, Argentina Lithium, and Algernon Pharmaceuticals

Finanznachrichten News

VANCOUVER, BC / ACCESSWIRE / January 19, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Xali Gold, Falcon Gold, Psyched Wellness, Argentina Lithium, and Algernon Pharmaceuticals discussing their latest press releases.

The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

Xali Gold (TSXV:XGC) applies for drilling permits at El Oro, Mexico

Xali Gold (XGC) has started a new drilling permit application process for the El Oro gold-silver Project in Mexico. New drill targets have been identified using a three-dimensional Leapfrog model and are designed to test potential extensions to high-grade gold and silver zones intersected by previous drilling. Joanne Freeze, President and CEO of Xali Gold sat down with Caroline Egan to discuss the news.

For the full interview with Joanne Freeze and to learn more about Xali Gold's drilling permit application, click here.

Falcon Gold (TSXV:FG) acquires 10,150 hectares in Gander North

Falcon Gold (FG) has staked 406 claims totalling 10,150 hectares in Newfoundland's Gander North area. The company will begin high-resolution magnetic surveys upon approval of exploration permits. The claims are located 25 km east of New Found Gold's Queensway Project and are contiguous to Sassy Resources' Gander North Project, which recently sampled 1,432 ppb gold. CEO Karim Rayani joined Dave Jackson to discuss the new claims.

For the full interview with Karim Rayani and to learn more about Falcon Gold's acquisition in Gander North, click here.

Psyched Wellness (CSE:PSYC) announces partnership with Vantage Hemp Co

Psyched Wellness (PSYC) has announced a manufacturing partnership with Vantage Hemp Co. The agreement includes extraction, commercial production and bottling of the products. Psyched Wellness will present a product derived from the Amanita Muscaria mushroom that is safe for human consumption using its proprietary extract, AME-1. David Shisel, COO of Psyched Wellness sat down with Dave Jackson to discuss the partnership.

For the full interview with David Shisel and to learn more about Psyched Wellness' partnership with Vantage Hemp Co, click here.

Argentina Lithium (TSXV:LIT) options additional properties on Pocitos Salar

Argentina Lithium & Energy (LIT) is expanding its holdings at the Pocitos Salar, at the heart of Argentina's world-renowned Lithium Triangle. The company's holdings in this salar now total over 26,000 hectares. Argentina Lithium President & CEO Nikolaos Cacos sat down with Dave Jackson to discuss the news.

For the full interview with Nikolaos Cacos and to learn more about Argentina Lithium's expansion at Pocitos Salar, click here.

Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The primary focus of the Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT helping Algernon plan its Phase 2 study more effectively. Christopher J. Moreau CEO of Algernon Pharmaceuticals sat down with Dave Jackson to discuss the news.

For the full interview with Christopher J. Moreau and to learn more about Algernon Pharmaceuticals' filing, click here.

Interviews for The Power Play by The Market Herald are released daily. To learn more about the companies featured in The Power Play or to explore our other interviews visit The Power Play by The Market Herald.

About The Market Herald

The Market Herald Canada is the leading source of authoritative breaking stock market news for self-directed investors. Our team of Canadian markets reporters, editors and technologists covers the entire listed company universe in Canada. We cover over 3,985 businesses, their people, their investors, and their customers. We write the stories that move the Canadian capital markets.

DISCLAIMER: Report Card Canada Media Ltd. ("Report Card") is a wholly-owned subsidiary of Market Herald Limited, an Australian company ("Market Herald"). Report Card is not an advisory service, and does not offer, buy, sell, or provide any other rating, analysis or opinion on the securities we discuss. We are retained and compensated by the companies that we provide information on to assist them with making information available to the public. All information available on themarketherald.ca and/or this press release should be considered as commercial advertisement and not an endorsement, offer or recommendation to buy or sell securities. Report Card is not registered with any financial or securities regulatory authority in any province or territory of Canada, will not be performing any registerable activity as defined by the applicable regulatory bodies and do not provide nor claim to provide investment advice or recommendations to any visitor of this site or readers of any content on or originating from themarketherald.ca. Market Herald and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Market Herald's affiliates. In such instances, Market Herald and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Market Herald and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize any conflict. All the information on this document and/or the website - themarketherald.ca - is published in good faith and for general information purpose only. Report Card does not make any warranties about the completeness, reliability, and accuracy of this information. Any action you take upon the information you find on this document and/or website (themarketherald.ca) is strictly at your own risk. Report Card will not be liable for any losses and/or damages in connection with the use of our website. From our website, you can visit other websites by following hyperlinks to such external sites. While we strive to provide only quality links to useful and ethical websites, we have no control over the content and nature of these sites. These links to other websites do not imply a recommendation for all the content found on these sites. Site owners and content may change without notice and may occur before we have the opportunity to remove a link which may have gone 'bad'. Please be also aware that when you leave our website, other sites may have different privacy policies and terms which are beyond our control. Please be sure to check the Privacy Policies of these sites as well as their "Terms of Service" before engaging in any business or uploading any information.

CONTACT:

The Market Herald
Brianna Anthony
brianna.anthony@themarketherald.ca
themarketherald.ca

SOURCE: The Market Herald



View source version on accesswire.com:
https://www.accesswire.com/684654/The-Power-Play-by-The-Market-Herald-Releases-Interviews-With-Xali-Gold-Falcon-Gold-Psyched-Wellness-Argentina-Lithium-and-Algernon-Pharmaceuticals

© 2022 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.